Publications Database

Anagnostou E. et al. (2006)

Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.

Journal of Clinical Psychopharmacology

26(4), pp. 444-446

Anagnostou E. , Hansen R. L. (2011)

Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications.

Current Opinions in Pediatrics

23(6), pp. 621-627.

Read Abstract (New Window)

Baribeau D. A. , Anagnostou E. (2014)

An update on medication management of behavioral disorders in autism.

Current Psychiatry Reports

16(3), pp. 437

Read Abstract (New Window)

Bates G. , Willson S. W. (2003)

'Use of selective serotonin reuptake inhibitors in children with pervasive developmental disorder: risk of treatment emergent mania'.

Developmental Medicine and Child Neurology

45(5), p.359; author reply p.360

Bethea T. C. , Sikich L. (2007)

Early pharmacological treatment of autism: a rationale for developmental treatment.

Biological Psychiatry

61(4), pp. 521-537

Read Abstract (New Window) Read Full (New Window)

Bhardwaj A. , Agarwal V. , Sitholey P. (2005)

Asperger's disorder with co-morbid separation anxiety disorder: A case report.

Journal of Autism and Developmental Disorders

35(1), pp. 135-136

Bishop J. R. et al. (2015)

Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.

Pharmacogenetics and Genomics

November, 25(11), pp. 548-554.

Read Abstract (New Window)

Boyd K. , Woodbury-Smith M. R. , Szatmari P. (2011)

Managing anxiety and depressive symptoms in adults with autism-spectrum disorders.

Journal of Psychiatry and Neuroscience

36(4), E 35-36

Read Full (New Window)

Buchsbaum M. (2001)

Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study

International Journal of Neuropsycholpharmacology

4(2), pp. 119-125

Read Abstract (New Window)

Canitano R. , Scandurra V. (2011)

Psychopharmacology in autism: An update.

Progress in Neuro-Psychopharmacology and Biological Psychiatry

35(1), pp. 18-28.

Read Abstract (New Window)

Carrasco M. , Volkmar F. R. , Bloch M. H. (2012)

Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: Evidence of publication bias.

Pediatrics

129(5), e1301-e1310.

Read Abstract (New Window) Read Full (New Window)

NHS Choices (2006)

Antidepressants.

London: National Health Service

Read Full (New Window)

Consoli A. et al. (2010)

Lorazepam, fluoxetine and packing therapy in an adolescent with pervasive developmental disorder and catatonia.

Journal of Physiology Paris

104(6), pp. 309-314.

Read Abstract (New Window)

Coury D. (2011)

Review: little evidence of clear benefit for most medical treatments for children with autism spectrum disorders.

Evidence Based Mental Health

May, 127(5),

Read Abstract (New Window) Read Full (New Window)

Couturier J. . L. , Nicolson R. (1992)

A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

12(3), pp. 243-248

Read Abstract (New Window)

DeLong G. R. , Teague L. , McSwain K. M. (1998)

Effects of fluoxetine treatment in young children with idiopathic autism

Developmental Medicine and Child Neurology

40(8), pp. 551-562

Read Abstract (New Window)

Dinca O. , Paul M. , Spencer N. (2005)

Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorder.

Journal of Psychopharmacology

19(5), pp. 521-532

Read Abstract (New Window)

Dove D. et al. (2012)

Medications for adolescents and young adults with autism spectrum disorders: A systematic review.

Pediatrics

130(4), pp. 717 -726.

Read Abstract (New Window)

Eissa N. et al.

Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder.

Frontiers in Neuroscience

Read Full (New Window)

Figgitt D. P. , McClellan K. J. (2000)

Fluvoxamine: An updated review of its use in the management of adults with anxiety disorders

Drugs

60(4), pp. 925-954

Read Abstract (New Window)